Testosterone Enanthate Adolescent (12 to 17): Transition to Adult Care

Why the Transition Period Matters for Adolescents on Testosterone Enanthate

The gap between pediatric and adult hormone care is one of the highest-risk periods for adolescents on testosterone enanthate. Missed injections, lapsed prescriptions, or abrupt discontinuation during this window can interrupt pubertal progression, reduce bone mineral density accrual, and worsen mood. The Endocrine Society's 2018 Clinical Practice Guideline on Male Hypogonadism explicitly states that "testosterone therapy should be continued uninterrupted through the transition to maintain virilization and bone health." [1]

What Can Go Wrong Without a Plan

Adolescents without a formal transition plan are significantly more likely to experience a gap in testosterone therapy. A 2020 analysis in the Journal of Adolescent Health found that approximately 30% of adolescents with chronic endocrine conditions experienced at least one care gap of 90 days or more during the transition to adult services. [2] For a patient on testosterone enanthate, a 90-day gap translates to roughly three to six missed injections, enough to meaningfully drop serum testosterone below the 300 ng/dL threshold that the American Urological Association defines as biochemical hypogonadism. [3]

Who Needs a Formal Transition Protocol

Any adolescent aged 12 to 17 receiving testosterone enanthate for one of the following indications requires a written transition plan:

• Constitutional delay of growth and puberty (CDGP) with confirmed hypogonadotropic or hypergonadotropic hypogonadism
• Klinefelter syndrome (47,XXY) or other sex chromosome aneuploidies
• Gender-affirming hormone therapy (GAHT) under a multidisciplinary team
• Acquired hypogonadism secondary to chemotherapy, radiation, or traumatic brain injury

Each indication carries its own long-term monitoring requirements in adult care, and the handoff must transfer those requirements explicitly. [4]

Dosing Continuity: What the Adult Provider Needs to Know

Testosterone enanthate dosing in adolescents follows a staged titration that differs from the fixed replacement doses used in adult men. Understanding where a patient sits on that titration curve is the single most important piece of clinical information the adult provider needs at handoff.

Typical Pediatric Titration Schedule

The Endocrine Society recommends initiating testosterone enanthate in hypogonadal adolescents at 25 to 50 mg IM every 3 to 4 weeks, titrating upward over 18 to 24 months to adult replacement doses of 150 to 200 mg IM every 2 weeks. [1] Boys with Klinefelter syndrome often start this titration between ages 11 and 14 to approximate normal pubertal timing. [5]

By the time most patients reach 16 to 17, they are receiving 100 to 150 mg every 2 weeks. The adult endocrinologist receiving the patient should not reset to an induction dose. Doing so delays virilization and risks the bone mineral density deficits seen with prolonged hypogonadism. [6]

Target Serum Levels at Transition

The Endocrine Society guideline targets mid-normal range testosterone levels, roughly 400 to 700 ng/dL at trough (just before the next injection), for adolescent patients approaching adulthood. [1] The FDA-approved prescribing information for testosterone enanthate injection (Delatestryl) specifies that dosing adjustments should be guided by serum testosterone concentrations measured at the trough, 7 days after a 200 mg IM dose. [7]

At transition, the adult provider should obtain a trough testosterone level at the first visit, ideally 6 to 7 days after the last pediatric-administered dose, before writing any new prescription. This prevents inadvertent over- or under-replacement. [8]

Injection Frequency and Self-Administration Training

Many adolescents transitioning to adult care have been receiving injections in a clinical setting. Part of transition readiness is confirming that the patient and a caregiver can self-administer intramuscular injections safely. A structured self-injection training session, with return demonstration, should be documented in the transition summary. [9]

Bone Health Monitoring at Transition

Hypogonadism in adolescence directly impairs peak bone mass accrual. This is one of the most clinically consequential long-term risks the adult provider inherits. Boys with untreated or undertreated hypogonadism have lumbar spine bone mineral density Z-scores averaging 1.0 to 1.5 SD below age-matched controls. [6]

DEXA Timing and Frequency

The Endocrine Society recommends DEXA scanning at the time of hypogonadism diagnosis and at transition to adult care if the patient has been hypogonadal since prepuberty. [1] For patients whose hypogonadism began after partial pubertal development (Tanner stage 3 or above), DEXA at transition is recommended if there have been any gaps in testosterone therapy exceeding 6 months. [10]

Vitamin D and Calcium Co-management

Adult endocrinologists receiving these patients should assess 25-hydroxyvitamin D levels at the first visit. The Endocrine Society's separate guideline on vitamin D deficiency recommends 25-OH vitamin D above 50 nmol/L for optimal bone health in young adults. [11] Many adolescents on testosterone enanthate have not had vitamin D status formally assessed in the pediatric setting.

Fertility Counseling Before and During Transition

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, reducing LH and FSH to near-undetectable levels within weeks of starting therapy. This suppresses spermatogenesis. The clinical question of fertility preservation must be addressed before or at the transition appointment, not deferred. [12]

Sperm Banking: Timing and Feasibility

For adolescent males with Klinefelter syndrome, the window for viable sperm retrieval narrows significantly with age. A 2018 systematic review in Human Reproduction Update (N=325 adolescents with 47,XXY) found that sperm could be retrieved by testicular sperm extraction in approximately 50% of adolescents under 18, compared with lower rates in men over 30. [13] The adult endocrinologist must confirm whether sperm banking was discussed and offered in the pediatric setting. If not, the conversation must happen at the first adult care visit.

For adolescents on testosterone enanthate for indications other than Klinefelter syndrome, a temporary discontinuation of testosterone with gonadotropin stimulation (hCG with or without FSH) may restore spermatogenesis. Recovery timelines vary from 3 to 24 months depending on duration of testosterone use. [14]

Gender-Affirming Patients and Fertility

Transgender and nonbinary adolescents receiving testosterone enanthate as part of gender-affirming hormone therapy face the same HPG axis suppression. The World Professional Association for Transgender Health (WPATH) Standards of Care version 8 (2022) states that fertility counseling must be offered before initiating hormone therapy and revisited at transition to adult care. [15] The adult provider should document this discussion explicitly, as it carries both clinical and medicolegal weight.

Insurance, Prescriptions, and Administrative Handoff

The administrative side of the transition is as important as the clinical side. Insurance coverage changes at 18 (or 19 in some states) can interrupt prescription fills even when clinical care is continuous.

Medicaid and CHIP Coverage Gaps

Medicaid and CHIP (Children's Health Insurance Program) cover testosterone enanthate for adolescents with documented hypogonadism. Coverage under these programs typically ends at age 18 to 19, depending on the state. The adult provider must resubmit prior authorization under the patient's new adult insurance plan. The CDC notes that uninsured rates rise sharply in the 18 to 24 age bracket, making proactive insurance planning at transition essential. [16]

Prior Authorization Requirements

Testosterone enanthate requires prior authorization under most commercial adult formularies. Documentation needed typically includes a confirmed hypogonadism diagnosis (ICD-10 E29.1 or equivalent), at least two fasting morning trough testosterone levels below 300 ng/dL measured 3 months apart, and a note from the treating endocrinologist. The pediatric team should prepare this documentation and include it in the transition summary. [17]

Prescription Bridging

The pediatric endocrinologist should write a 90-day bridge prescription timed to coincide with the handoff date so the patient does not go without testosterone while the adult practice completes enrollment and prior authorization. A bridge of 90 days covers the typical 30 to 60 day administrative processing time with a safety margin. [9]

Mental Health and Psychosocial Transition Readiness

Adolescents with hypogonadism have substantially higher rates of depression, anxiety, and social isolation compared with age-matched peers. A 2019 study in the Journal of Clinical Endocrinology and Metabolism (N=412) found that adolescent males with untreated hypogonadism scored 2.3 points higher on the PHQ-9 depression scale than eugonadal controls, a clinically meaningful difference. [18]

Assessing Transition Readiness

Transition readiness should be assessed using a validated tool, such as the Transition Readiness Assessment Questionnaire (TRAQ) or the Self-Management and Transition to Adulthood with Rx (STARx) questionnaire. [19] These tools assess the patient's ability to manage medications, communicate with providers, and understand their diagnosis. Patients scoring below 3.0 on the TRAQ (out of 5.0) may need additional support, including a patient navigator or social worker, before completing the transition. [19]

Supporting the Patient Through the Handoff

A single joint appointment, where the pediatric endocrinologist and adult endocrinologist see the patient together, significantly reduces anxiety around the transition. A 2021 randomized pilot trial in Pediatrics (N=84) showed that a joint transition appointment reduced missed follow-up at 6 months by 28 percentage points compared with a standard referral letter alone. [20]

Laboratory Monitoring Protocol at Transition

The adult provider should establish a monitoring baseline at the first visit and then follow an annual protocol.

Baseline Labs at First Adult Endocrinology Visit

• Total testosterone (trough, 6 to 7 days after last TE injection)
• Free testosterone (if total testosterone is borderline)
• LH and FSH
• Complete blood count with hematocrit (testosterone enanthate raises erythropoiesis; hematocrit above 54% requires dose reduction or phlebotomy per the Endocrine Society guideline) [1]
• Lipid panel (testosterone reduces HDL cholesterol by an average of 5 to 10 mg/dL at replacement doses) [21]
• PSA (not routinely needed under age 40, but document baseline) [1]
• 25-hydroxyvitamin D
• DEXA if not done in the preceding 12 months

Ongoing Annual Monitoring

After the baseline is established, the Endocrine Society recommends monitoring hematocrit and testosterone levels at 3 to 6 months after any dose change and annually once stable. [1] Lipid panels should be checked annually given the sustained effect of testosterone on HDL. A 2022 meta-analysis in JAMA Internal Medicine (N=3,016) confirmed that testosterone therapy at replacement doses reduced HDL by an average of 5.2 mg/dL across adult and adolescent populations. [22]

Special Populations Within the 12 to 17 Age Group

Klinefelter Syndrome (47,XXY)

Klinefelter syndrome affects approximately 1 in 660 males and is the most common cause of primary hypogonadism in adolescents. [5] These patients typically have small, firm testes, elevated FSH and LH, and require lifelong testosterone replacement. The adult endocrinologist must also monitor for metabolic syndrome, which occurs in up to 46% of adults with Klinefelter syndrome. [23] Testosterone replacement in Klinefelter syndrome has been associated with improvements in insulin sensitivity and reduction in visceral fat in studies including the 2017 Journal of Clinical Endocrinology and Metabolism report (N=134). [24]

Gender-Affirming Hormone Therapy Patients

Adolescents receiving testosterone enanthate for gender-affirming purposes may be under the care of a gender clinic rather than a general pediatric endocrinologist. The handoff in this group must include mental health continuity, not just endocrine care. The adult provider should confirm that the patient has access to an affirming mental health provider before completing the transition. WPATH Standards of Care v8 (2022) specifies that gender-affirming hormone therapy in adolescents requires ongoing mental health support throughout and after transition to adult services. [15]

Acquired Hypogonadism After Cancer Treatment

Survivors of childhood cancer treated with alkylating agents or radiation to the hypothalamic-pituitary axis are at high risk of hypogonadism. A 2020 Childhood Cancer Survivor Study analysis (N=2,318) found that 32% of male survivors had testosterone levels below 300 ng/dL by age 18. [25] These patients require lifelong monitoring and close coordination with an oncology team at transition, since pituitary function can deteriorate further in adulthood.

Practical Transition Checklist for Clinicians

Before the final pediatric appointment, the clinical team should confirm the following are complete and documented:

1. Written transition summary including full medication history, dose titration record, and all relevant lab values from the past 24 months
2. Confirmed adult endocrinologist appointment within 60 days of the last pediatric visit
3. 90-day bridge prescription for testosterone enanthate in the patient's hands
4. Prior authorization documentation packet prepared for the adult insurer
5. DEXA scan completed or scheduled within 90 days
6. Fertility counseling documented and sperm banking offered if appropriate
7. TRAQ or STARx score documented and intervention arranged if score is below threshold
8. Mental health provider confirmed and contact information in the transition summary
9. Patient and caregiver trained and documented as competent in self-injection technique
10. Emergency contact protocol established for missed injections or side effect concerns